#United States #New York #Shareholders #Lawsuit #Regeneron

Key Updates for Regeneron Pharmaceuticals Investors

Investors who purchased securities from Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between August 1, 2025, and May 15, 2026, should take note of a securities class action lawsuit that has recently been filed. A significant date is approaching: September 14, 2026, will mark the deadline for shareholders to file to be appointed as the lead plaintiff in this case.

Allegations Against Regeneron

The lawsuit primarily stems from allegations that Regeneron failed to adequately disclose material risks associated with its Fianlimab-Libtayo Phase III trial. It is claimed that the company downplayed various statistical and protocol risks, particularly concerning the implications of FDA-related amendments that could affect progression-free survival analysis.

As a result, REGN’s stock price has experienced a notable decline. Specifically, shares dropped $102.09 or 13.95%, from a peak of $731.77 on April 28, 2026, to $629.68 after the concerning disclosures regarding the clinical study.

Core Legal Challenges

The crux of the lawsuit revolves around whether Regeneron gave sufficient disclosures regarding the risks inherent in their clinical studies. The complaint alleges that public comments made by the company did not adequately reflect the potential failure risks tied to the study’s design and statistical validity. Key points of concern from the complaint include:

• - Investors were reportedly not made aware that a slowdown in progression-free survival event accrual could lead to clinical failure.
• - The statistical design of the study apparently left it vulnerable to not achieving its primary endpoint.
• - There were claims that the active treatment group did not demonstrate significant clinical advantages over existing standard therapies, including pembrolizumab.
• - A protocol amendment included all patients with a minimum of six months follow-up for the PFS analysis, which later proved problematic.
• - Ultimately, the study did not achieve statistical significance concerning its primary endpoint of improved progression-free survival.

SEC Disclosure Concerns

The complaint raises issues regarding the adequacy of Regeneron's disclosures as mandated by the Securities and Exchange Commission (SEC). Critics argue that the company misrepresented the risks associated with their clinical trial, thus misleading investors.

On April 29, 2026, Regeneron revealed a protocol change to include a larger set of patients in the analysis. Then on May 15, after market hours, the company announced that it could not meet the primary endpoint of improved progression-free survival in the Phase III trial, which contributed to the decline in stock value. This lawsuit raises critical questions about how much the company knew regarding these issues before the disclosures were made.

Role of the Lead Plaintiff

Being appointed as the lead plaintiff is essential for representing the class of affected investors. Typically, the lead plaintiff is someone with substantial losses, and their role is to oversee the lawsuit's proceedings. However, being designated does not guarantee a higher recovery for their losses.

FAQs Regarding the Lawsuit

1. What is the essence of the REGN class action lawsuit?
The securities class action lawsuit targets Regeneron Pharmaceuticals, asserting that the company made materially misleading statements regarding the Phase III Fianlimab-Libtayo study. As a result, investors who bought shares during the class period and suffered losses may qualify for compensation.

2. Where was the REGN class action filed?
This case was filed in the United States District Court for the Southern District of New York and will follow the guidelines of the Private Securities Litigation Reform Act of 1995.

3. Can I still recover losses if I already sold my shares?
Yes, the eligibility for participation relies on when shares were purchased, not whether they are still held. Investors who sold during the class period and incurred losses may still be entitled to recover.

Generally, there is no upfront cost to join the class action. These types of lawsuits operate on a contingency basis, ensuring that investors only pay if there is a successful recovery.

In summary, if you or someone you know has invested in Regeneron Pharmaceuticals during the specified period, it’s crucial to pay attention to the September 14 deadline and consider your legal options moving forward.